Silver Spring-based United Therapeutics (NASDAQ: UTHR) finished off 2013 with a strong showing, collecting revenues of over $1.1 billion for the first time in its corporate history as well posting a net profit for the full-year 2013 and upbeat 2014 outlook.
Hidden beneath all the earnings news is a very important line segment on the balance sheet called “Cash and Cash Equivalents”. These are assets that have high liquidity and can be easily converted to cash or are cash themselves; that being said United Therapeutics has amassed nearly $1.14 billion worth of it. The amount is over $350 million more than the company held at the end of 2012.